Focused On-demand Library for Major facilitator superfamily domain-containing protein 8

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q8NHS3

UPID:
MFSD8_HUMAN

ALTERNATIVE NAMES:
Ceroid-lipofuscinosis neuronal protein 7

ALTERNATIVE UPACC:
Q8NHS3; B2RDM1; B7Z205; Q8N2P3

BACKGROUND:
The protein known as Ceroid-lipofuscinosis neuronal protein 7, or Major facilitator superfamily domain-containing protein 8, is implicated in the essential biological process of solute transport using chemiosmotic ion gradients. Its function underscores the protein's importance in cellular physiology and its potential role in disease mechanisms.

THERAPEUTIC SIGNIFICANCE:
Linked to severe disorders like neuronal Ceroid lipofuscinosis type 7 and Macular dystrophy with central cone involvement, the study of Major facilitator superfamily domain-containing protein 8 offers a promising avenue for the development of targeted therapies. These diseases, affecting the nervous system and vision, respectively, underscore the therapeutic importance of this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 129 of 8789